Cases: Healthcare suppliers

Default Image - Pharma
Performing a health-economic evaluation (budget impact analysis) of a proposed adaptation of the reimbursement criteria for certain implants in Belgium.
Novartis logo
A large international pharmaceutical company had applied for Class 1 reimbursement of a specific drug for adult patients with myelofibrosis. The company asked hict for...
Orion Logo
Orion  Orion is a Finnish, Espoo–based pharmaceutical company with branches across Europe. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical...
Logo BD
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD wants to investigate the market interest...
Qualitative market research: Clinical Practice DVT & PE in 10 Belgian hospitals
This market research was performed to support a pharmaceutical company in the launch of 2 new indications for Product X (New Oral Anticoagulant): acute treatment and prevention of DVT (Deep vein...
Our client wants to support their marketing teams in 8 European countries with correct data to optimise the sales forecast for a certain medicine. To date big differences were noticed during...
Abbott Diagnostics - Quantifying the added value of Abbott Architect instrumentation and process optimisations in the Kostanay Blood Bank Infectious Diseases Screening Lab [Whitepaper]
The present study aims to quantify, in monetary value, the added value of process improvements and cost reductions realized as a result of implementing Abbott Architect instrumentation and associated...
Lundbeck - Perform a budget impact analysis for the second class reimbursement submission of a long-acting injectable drug for the maintenance treatment of schizophrenia in Belgium.
Lundbeck asked hict for support in developing a budget impact analysis (BIA) for the reimbursement submission of Abilify Maintena®, a long-acting injectable drug for the maintenance treatment of...
Janssen Pharmaceutica - Innovative business development: Blue print public health innovation project HCV disease management in Romania
hict supported Janssen in het project that envisioned that Romania will lead the world with best-in-class HCV management and research by 2020 and enters a new public health care era in modern...
Ezelstraat 69 | B- 8000 Brugge | Belgium | Phone: +32.50.33.33.40 | Fax: +32.50.33.33.39 | BTW BE 0866 039 556 | RPR/RPM Brugge | e-mail: info@hict.com